多巴胺D<sub>3</sub>受体配体研究现状

朱爱芝

多巴胺D₃受体配体研究现状

朱爱芝

文章导航 > 国际放射医学核医学杂志 > 2002, 26 > 2: (53-56)

引用本文:

Citation:

多巴胺D₃受体配体研究现状

朱爱芝

100003 北京, 中国科学院髙能物理研究所

作者简介: 朱爰芝(1971-),河北迁安人,博士,主要从事核药物的研究。;

基金项目:
中国科学院知识创新工程资助项目(U-516-3)
中图分类号: R962

The research status of dopamine D₃ receptor ligands

ZHU Ai-zhi

Laboratory of Nuclear Analysis Techniques, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100039, China
CLC number: R962

摘要: 综述了现有多巴胺D₃受体配体(主要是氨基四氢萘满类)的分子结构、受体亲和性和受体选择性进行了比较,并对多巴胺D_{3_{受体配体的研究进行了展望。}}
- 多巴胺 /
- D₃受体 /
- 配体 /
- 四氢氨基萘满
Abstract: Dopamine D₃ receptor ligands were reviewed in this paper. Aminotetralin derivatives is a main kind of them. After comparing the molecule structure, receptor affinity and receptor selectivity of them, I made a prospective research future of high selective and affinity ligands of dopamine D₃ receptor.
- dopamine /
- D₃receptor /
- ligand /
- aminotetralin
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Lévesque D,Siaz J,Pilon C, et al. Identification,characterization,and localization of the dopamine D3 receptor in rat brain using 7-[³H] hydroxy-N,N-di-n-propyl-2-aminotetralin[J].Proc Natl acad Sci,1992,89:8155-8159.
[2]	Gonzalez AM,Sibley D R. [³H] 7-OH-DPAT is capable of labeling dopamine D₂ as well as D₃ receptors[J].Eur J Pharmacol,1995,272:R1-R3.
[3]	Damsma G,Bottema T,Weserink B H C, et al. Pharmacological aspects of R-(+)-7-OH-DPAT,a putative dopamine D₃ receptor ligand[J].Eur J Pharmacol,1993,249:R9.
[4]	Van Vliet A,Tepper PG,Dijkstra D, et al. Affinity for Dopamine D₂,D₃ and D₄ Receptors of 2-aminotetrahns relevance of D₂ agonist binding for determination of receptor subype selectivity[J].J Med Chem,1996,39,4233-4237.
[5]	Wallace DR,Booze RM. Identification of D₃ and σ receptors in the rat striatum and nucleus accumbens using(±)-7-Hdroxy-N,N-Di-n-[³H] Propyl-2-aminotetralin and carbetapentane[J].J Neurochem,1995,64:700-710.
[6]	Foulon C,Kung MP,Kung HF, et al. Synthesis of(R S)-2'-trans-7-hydroxy-2-[N-(3'-iodo-2'-prope-nyl)-N-n-propyl] Aminotetralin(trans-7-OH-PIPAT)[J].J Med Chem,1994,36:1499-1500.
[7]	Chumpradit S,Kung M P,Kung H F, et al. Synthesis and optical resolution of(R)-and(S)-trans-7-Hydroxy-2-[N-propyl-N-(3'-iodo-2'-propenyl)amino] tetralin:a new D₃ Dopamine Receptor Ligand[J].J Med Chem,1993,36:4308-4312.
[8]	Kung MP,Kung H F,Foulon C, et al. In Vitro Binding of a Novel Dopamine D₃ Receptor Ligand:[¹²⁵I] trans-7-OH-PIPATA[J].Eur J Pharmacol,1993,235:165-166.
[9]	Burris KD,Filtz T,Chumpradit S, et al. Characterization of[¹²⁵I] -(R)-2'-trans-7-Hydroxy-2-[N-n-Propyl-N-(3'-iodo-2'-propenyl)amino] tetralin([¹²⁵I] (R) trans-7-OH-PIPAT) binding to dopamine D₃ receptors in rat olfactory tubercle[J].J Pharmacol Exp Ther,1994,268,935-942.
[10]	Chumpradit S,Kung MP,Vessotskie J, et al. Iodinated 2-aminotetralins and 3-Amino-l-benzopyrans:Ligands for dopamine D₂ and D₃ receptors[J].J Med Chem,1994,37,4245-4250.
[11]	Vessotskie J,Kung MP,Chumpradit S, et al. Quantitative autoradiographie studies of dopamine D₃ receptors in rat cerebellum using [¹²⁵I] S(-)5-OH-PIPAT[J].Brain Res,1997,778:89-98.
[12]	Avenell KY,Boyfield I,Coldwell M C, et al. Fused aminotetralins:Novel antagonists with high selectivity for the dopamine D₃ receptor[J].Bioorg Med Chem Letts,1998,8:2859-2864.
[13]	Austin NE,Avenell KY,Boyfield I, et al. Design and Synthesis of Novel 2,3-Dihydro-¹H-isoindoles with high affinity and selectivity for the dopamine D₃ receptor[J].Bioorg Med Chem Letts,2001,11:685-688.
[14]	Akunne HC,Towers P,Ellis GJ, et al. Characterization of binding of [³H] PD128907,a selective dopamine D₃ receptor agonist ligand,to CHO-K1 Cells[J].Life Sci,1995,57(15):1401-1410.
[15]	Millan MJ,Audinot V,Rivet J, et al. S14279,A novel,selective ligand at cloned dopamine D₃ receptors,blocks 7-OH-DPAT-indueee hypothermia in rats[J].Eur J Pharmacol,1994,260,R3-R5.
[16]	Rivet JM,Audinot V,Gobert A, et al. Modulation of mesolimbie dopamine release by the selective dopamine D₃ receptor antagonist,(+)S14297[J].Eur J Pharmacol,1994,265:175-177.
[17]	Mierau J,Schneider FJ,Ensinger HA, et al. Pramipexole binding and activation of cloned and expressed dopamine D₂,D₃ and D₄ receptors[J].Eur J Pharmacol-Mol Pharmacol Sec,1995,290,29-36.
[18]	Wallace DR,Booze RM. Pramipexole,a dopamine D₂-preferring compound that lacks interactions with sigma binding sites[J].Neurosci Res Commun,1995,17:177.
[19]	Piereey MF,Walker EL,Feldpauseh DL, et al. High affinity binding for pramipexole,a dopamine D₃ receptor ligand in rat striatum[J].Neurosci Lett,1996,219,138-140.
[20]	Murray PJ,Harrison LA,Johnson MR, et al. A novel series of Arylpiperazines with high affinity and selectivity for the dopamine D₃ receptor[J].Bioorg Med Chem Lett,1995,5(3):219-222.

[1]	张旭光 . 局部注射放射性核素治疗实体瘤的探讨. 国际放射医学核医学杂志, 2002, 26(3): 105-108118.
[2]	袁杰 , 刘兴党 , 韩梅 . SPECT、PET神经受体和转运体显像技术在海洛因成瘾研究中的应用. 国际放射医学核医学杂志, 2013, 37(1): 30-33, 41. doi: 10.3760/cma.j.issn.1673-4114.2013.01.009
[3]	杨敏 . ¹²³I-epidepride:多巴胺D₂受体显像剂. 国际放射医学核医学杂志, 2000, 24(2): 67-70.
[4]	杨敏 . ¹⁸F-fallypride:一种多巴胺D2受体PET显像剂. 国际放射医学核医学杂志, 2003, 27(6): 259-262.
[5]	曹国祥 , 谭天秩 . 多巴胺受体及其SPECT显像研究. 国际放射医学核医学杂志, 1998, 22(2): 69-72.
[6]	任均田 . 以MAG3为配体的¹⁸⁶Re标记单克隆抗体:配体数目与生物学分布的关系. 国际放射医学核医学杂志, 1997, 21(3): 121-121.
[7]	袁洪卫 , 林汉 . G蛋白偶联受体及其配体的结构与功能分析. 国际放射医学核医学杂志, 1996, 20(3): 112-115.
[8]	曹国祥 , 谭天秩 . 多巴胺受体显像剂的研究概况. 国际放射医学核医学杂志, 1999, 23(2): 65-67.
[9]	李云春 , 管昌田 . 毒蕈碱受体SPECT显像的新配体IQNP的合成和生物学分布. 国际放射医学核医学杂志, 1994, 18(2): 91-92.
[10]	王荣福 . 多巴胺能神经递质及受体显像的临床研究和应用进展. 国际放射医学核医学杂志, 2000, 24(2): 59-62.